CompletedHealthcare3 February 2026

Erigen to acquire Tempest Therapeutics, Inc.

Verified deal facts, source-backed narrative, and the Exit Mode founder lens for SME readers preparing to sell.

Deal facts

Buyer
Erigen
Target
Tempest Therapeutics, Inc.
Deal value
Not disclosed
Announced
3 February 2026
Status
Completed
Sector
Healthcare
Country
United States
Consideration
shares
What we know

More M&A Tools

Explore the Toolkit

Tools, frameworks and AI assistants designed for entrepreneurs serious about M&A.

Access now

Deal timeline

1 update
  1. CompletedClosed

    Erigen completes acquisition of Tempest Therapeutics, Inc.

    Introductory Note. As previously disclosed, on November 19, 2025, Tempest Therapeutics, Inc. (the “ Company ”) executed an Asset Purchase Agreement (the “ Asset Purchase Agreement ”) with Erigen LLC, a Delaware limited liability company (“ Erigen ”), and Factor Bioscience Inc., a Delaware corporation (together with Erigen, “ Sellers ”), pursuant to which Sellers agreed to sell and transfer to the

    Source

Explore

Browse adjacent archives

Jump from this deal into the sector, buyer, deal type, and year views that carry the strongest contextual signal.

Similar deals

Similar deals

Other Healthcare M&A activity tracked by Exit Mode.

30 June 2026Firm intentionHealthcare

Public Company Management Corporation to acquire Physicians Capital Management Corporation

Public Company Management Corporation has agreed to acquire Physicians Capital Management Corporation in a strategic acquisition within the healthcare sector. The transa…

Buyer
Public Company Management Corporation
Target
Physicians Capital Management Corporation
Deal value
Not disclosed
Deal type
strategic acquisition

Buyer history

Erigen

See every published Exit Mode archive entry where this buyer appears.

View buyer profile

Methodology

How this page is built

Layer 1 facts come from source documents, Layer 2 turns those facts into a readable narrative, and Layer 3 only appears where the editorial team flags a founder-relevant deal.

Back to the archive